Premium
Incyte Corporation (INCY)
NASDAQ
Hot Features
Inscrivez-vous gratuitement pour obtenir des cotations en temps réel, des graphiques interactifs, un flux d'options en direct et plus encore.
| Date | Nom du détenteur | Actions transigées | Fourchette de valeur ($) | Type d'opération | Fourchette de prix ($) | Actions en fin de déclaration | % de variation |
|---|---|---|---|---|---|---|---|
| 2026-06-01 | Dr. Pablo J. CagnoniPresident and Global Head of R&D | -25,47k | 2,43M | Sale to Issuer | 95,59 | 27,77k | -47,84% |
| 2026-05-26 | Mr. Thomas TrayPrincipal Financial Officer, VP of Finance & CAO | -2,05k | 199,66k | Vente | 97,35 | 5,97k | -25,58% |
| 2026-05-26 | Mr. Jean-Jacques BienaimeIndependent Director | -13,06k | 164,15k | Derivative Exercise and Sale | 84,53 - 97,10 | 20,26k | - |
| 2026-05-26 | Mr. Jean-Jacques BienaimeIndependent Director | 1,94k | 164,07k | Derivative Exercise and Retained Stock | 84,53 | 20,26k | 10,59% |
| 2026-05-19 | Mr. Paul J. ClancyIndependent Director | -15,00k | 156,00k | Derivative Exercise and Sale | 84,53 - 94,93 | 21,22k | - |
| 2026-05-08 | Baker Bros. Advisors LPSociété | 30,00k | 2,54M | Derivative Exercise and Retained Stock | 84,53 | 31,07M | 0,10% |
| 2026-04-17 | Dr. Pablo J. CagnoniPresident and Global Head of R&D | -18,67k | 505,32k | Derivative Exercise and Sale | 64,25 - 96,50 | 5,14k | - |
| 2026-03-25 | Mr. Matteo TrottaInitié | -537,00 | 49,53k | Sale to Issuer | 92,23 | 3,72k | -12,61% |
| 2026-03-17 | Dr. Pablo J. CagnoniPresident and Global Head of R&D | -18,67k | 581,82k | Derivative Exercise and Sale | 61,18 - 94,24 | 5,14k | - |
| 2026-02-19 | Dr. Pablo J. CagnoniPresident and Global Head of R&D | -18,67k | 734,09k | Derivative Exercise and Sale | 61,18 - 100,91 | 5,14k | - |
| 2026-02-02 | Mr. Lee J. HeesonExec. VP & Head of Incyte International | -111,00 | 11,40k | Sale to Issuer | 102,67 | - | - |
| 2026-02-02 | Mr. Michael James MorrisseyExec. VP & Head of Global Technical Operations | -185,00 | 18,99k | Sale to Issuer | 102,67 | 11,51k | -1,58% |
| 2026-01-20 | Mr. Michael James MorrisseyExec. VP & Head of Global Technical Operations | -429,00 | 44,02k | Sale to Issuer | 102,62 | 9,05k | -4,52% |
| 2026-01-07 | Mr. Mohamed Khairie IssaExec. VP & Head of U.S. Commercial | -10,86k | 1,18M | Vente | 109,07 | - | - |
| 2026-01-06 | Mr. Mohamed Khairie IssaExec. VP & Head of U.S. Commercial | -8,26k | 881,44k | Sale to Issuer | 106,66 | - | - |
| 2026-01-05 | Dr. Steven H. SteinExec. VP, Head of Late-stage Development & Chief Medical Officer | -15,63k | 1,59M | Vente | 101,70 | 0,00 | -100,00% |
| 2025-12-31 | Dr. Steven H. SteinExec. VP, Head of Late-stage Development & Chief Medical Officer | -13,29k | 1,31M | Sale to Issuer | 98,77 | 15,63k | -45,95% |
| 2025-12-31 | Mr. Michael James MorrisseyExec. VP & Head of Global Technical Operations | -254,00 | 25,09k | Sale to Issuer | 98,77 | 3,36k | -7,03% |
| 2025-12-19 | Mr. Thomas TrayPrincipal Financial Officer, VP of Finance & CAO | -2,77k | 11,76k | Derivative Exercise and Sale | 95,76 - 100,00 | 7,81k | - |
| 2025-12-18 | Mr. Thomas TrayPrincipal Financial Officer, VP of Finance & CAO | -600,00 | 58,95k | Vente | 98,25 | 7,81k | -7,14% |
| 2025-12-16 | Mr. Michael James MorrisseyExec. VP & Head of Global Technical Operations | -58,33k | 5,68M | Vente | 97,26 - 97,42 | 0,00 | -100,00% |
| 2025-12-10 | Dr. Patrick MayesVP of Biotherapeutic Research | -5,81k | 554,97k | Vente | 94,94 - 95,58 | 153,00 | -97,43% |
| 2025-12-08 | Mr. Herve HoppenotInitié | -2,84k | 274,92k | Sale to Issuer | 96,70 | 256,16k | -1,10% |
| 2025-12-01 | Dr. Steven H. SteinExec. VP, Head of Late-stage Development & Chief Medical Officer | -22,66k | 2,32M | Vente | 102,51 - 102,96 | 0,00 | -100,00% |
| 2025-12-01 | Dr. Steven H. SteinExec. VP, Head of Late-stage Development & Chief Medical Officer | -17,09k | 1,74M | Sale to Issuer | 102,04 | 0,00 | -100,00% |
| 2025-12-01 | Mr. Michael James MorrisseyExec. VP & Head of Global Technical Operations | -326,00 | 33,27k | Sale to Issuer | 102,04 | 58,33k | -0,56% |
| 2025-11-21 | Mr. Thomas TrayPrincipal Financial Officer, VP of Finance & CAO | -769,00 | 79,04k | Vente | 102,00 - 103,00 | 8,41k | -8,38% |
| 2025-11-17 | Ms. Sheila A. DentonInitié | -278,00 | 11,15k | Derivative Exercise and Sale | 64,25 - 104,36 | 656,00 | - |
| 2025-11-10 | Mr. Herve HoppenotInitié | -187,50k | 19,77M | Vente | 105,46 | 256,16k | -42,26% |
| 2025-11-05 | Dr. Steven H. SteinExec. VP, Head of Late-stage Development & Chief Medical Officer | -5,23k | 47,94k | Derivative Exercise and Sale | 83,83 - 102,20 | 2,56k | - |
| 2025-11-04 | Ms. Sheila A. DentonInitié | -598,00 | 25,89k | Derivative Exercise and Sale | 58,06 - 101,36 | 656,00 | - |
| 2025-11-03 | Mr. Lee J. HeesonExec. VP & Head of Incyte International | -3,07k | 289,02k | Vente | 94,02 | - | - |
| 2025-10-15 | Ms. Sheila A. DentonInitié | -277,00 | 5,78k | Derivative Exercise and Sale | 64,25 - 85,13 | 656,00 | - |
| 2025-10-02 | Ms. Sheila A. DentonInitié | -599,00 | 17,72k | Derivative Exercise and Sale | 58,06 - 87,65 | 656,00 | - |
| 2025-10-03 | Ms. Sheila A. DentonInitié | -3,50k | 299,48k | Vente | 85,54 | 656,00 | -84,22% |
| 2025-10-02 | Ms. Sheila A. DentonInitié | -3,13k | 270,06k | Sale to Issuer | 86,28 | 656,00 | -82,67% |
| 2025-10-01 | Dr. Patrick MayesVP of Biotherapeutic Research | -1,57k | 136,03k | Sale to Issuer | 86,70 | 5,96k | -20,84% |
| 2025-10-01 | Mr. Lee J. HeesonExec. VP & Head of Incyte International | -463,00 | 40,14k | Sale to Issuer | 86,70 | - | - |
| 2025-09-16 | Ms. Sheila A. DentonInitié | -278,00 | 5,25k | Derivative Exercise and Sale | 64,25 - 83,15 | 657,00 | - |
| 2025-09-02 | Ms. Sheila A. DentonInitié | -598,00 | 16,09k | Derivative Exercise and Sale | 58,06 - 84,97 | 656,00 | - |
| 2025-08-15 | Ms. Sheila A. DentonInitié | -277,00 | 6,25k | Derivative Exercise and Sale | 64,25 - 86,81 | 657,00 | - |
| 2025-08-04 | Ms. Sheila A. DentonInitié | -598,00 | 10,59k | Derivative Exercise and Sale | 58,06 - 75,77 | 656,00 | - |
| 2025-07-21 | Dr. Steven H. SteinExec. VP, Head of Late-stage Development & Chief Medical Officer | -3,71k | 251,79k | Vente | 67,94 | 2,56k | -59,15% |
| 2025-07-16 | Dr. Barry P. FlannellyInitié | -1,34k | 91,60k | Vente | 68,36 | 13,00 | -99,04% |
| 2025-07-16 | Dr. Vijay K. IyengarInitié | -983,00 | 67,20k | Vente | 68,36 | 2,79k | -26,07% |
| 2025-07-15 | Ms. Sheila A. DentonInitié | -3,33k | 18,68k | Derivative Exercise and Sale | 64,25 - 69,86 | 656,00 | - |
| 2025-07-16 | Ms. Sheila A. DentonInitié | -785,00 | 53,66k | Vente | 68,36 | 656,00 | -54,48% |
| 2025-07-15 | Ms. Sheila A. DentonInitié | -703,00 | 47,98k | Sale to Issuer | 68,25 | 656,00 | -51,73% |
| 2025-07-15 | Mr. Matteo TrottaInitié | -182,00 | 12,42k | Sale to Issuer | 68,25 | 1,90k | -8,75% |
| 2025-07-14 | Dr. Pablo J. CagnoniPresident and Global Head of R&D | -3,91k | 268,94k | Sale to Issuer | 68,25 - 69,98 | 5,14k | -43,20% |
| 2025-07-14 | Ms. Paula J. SwainInitié | -1,01k | 69,50k | Sale to Issuer | 68,25 - 69,98 | 69,09k | -1,44% |
| 2025-07-14 | Dr. Steven H. SteinExec. VP, Head of Late-stage Development & Chief Medical Officer | -14,95k | 1,02M | Vente | 68,47 | 6,27k | -70,47% |
| 2025-07-14 | Dr. Steven H. SteinExec. VP, Head of Late-stage Development & Chief Medical Officer | -3,15k | 217,75k | Sale to Issuer | 68,25 - 69,98 | 6,27k | -33,46% |
| 2025-07-14 | Ms. Christiana StamoulisInitié | -2,85k | 197,08k | Sale to Issuer | 68,25 - 69,98 | 61,75k | -4,41% |
| 2025-07-15 | Dr. Vijay K. IyengarInitié | -1,18k | 82,23k | Vente | 69,86 | 3,77k | -23,79% |
| 2025-07-14 | Dr. Vijay K. IyengarInitié | -1,43k | 98,70k | Sale to Issuer | 68,25 - 69,98 | 3,77k | -27,51% |
| 2025-07-14 | Mr. Thomas TrayPrincipal Financial Officer, VP of Finance & CAO | -1,28k | 88,22k | Sale to Issuer | 68,25 - 69,98 | 9,15k | -12,23% |
| 2025-07-15 | Dr. Barry P. FlannellyInitié | -1,19k | 83,27k | Vente | 69,86 | 1,35k | -46,84% |
| 2025-07-14 | Dr. Barry P. FlannellyInitié | -2,06k | 142,39k | Sale to Issuer | 68,25 - 69,98 | 1,35k | -60,39% |
| 2025-07-14 | Mr. Herve HoppenotInitié | -9,67k | 668,83k | Sale to Issuer | 68,25 - 69,98 | 443,66k | -2,13% |
| 2025-07-02 | Ms. Paula J. SwainInitié | -6,29k | 428,45k | Sale to Issuer | 68,17 | 66,73k | -8,61% |
| 2025-07-02 | Mr. Thomas TrayPrincipal Financial Officer, VP of Finance & CAO | -897,00 | 61,15k | Sale to Issuer | 68,17 | 7,65k | -10,49% |
| 2025-07-02 | Dr. Steven H. SteinExec. VP, Head of Late-stage Development & Chief Medical Officer | -12,71k | 866,71k | Sale to Issuer | 68,17 | 17,51k | -42,06% |
| 2025-07-02 | Ms. Christiana StamoulisInitié | -11,59k | 790,02k | Sale to Issuer | 68,17 | 58,40k | -16,56% |
| 2025-07-03 | Dr. Barry P. FlannellyInitié | -10,90k | 743,04k | Vente | 68,15 | 13,00 | -99,88% |
| 2025-07-02 | Dr. Barry P. FlannellyInitié | -9,06k | 617,28k | Sale to Issuer | 68,17 | 13,00 | -99,86% |
| 2025-07-02 | Ms. Sheila A. DentonInitié | -599,00 | 6,32k | Derivative Exercise and Sale | 58,06 - 68,61 | 656,00 | - |
| 2025-07-03 | Dr. Vijay K. IyengarInitié | -8,62k | 587,28k | Vente | 68,15 - 68,16 | 2,79k | -75,55% |
| 2025-07-02 | Dr. Vijay K. IyengarInitié | -6,81k | 464,17k | Sale to Issuer | 68,17 | 2,79k | -70,95% |
| 2025-07-02 | Mr. Herve HoppenotInitié | -42,77k | 2,92M | Sale to Issuer | 68,17 | 432,28k | -9,00% |
| 2025-06-10 | Dr. Susanne SchaffertInitié | -849,00 | 59,49k | Sale to Issuer | 70,07 | 4,87k | -14,84% |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
S'inscrire avec l'e-mail
Vous avez déjà un compte? Connexion
Vous n'avez pas de compte ? Inscription
En m'inscrivant, je confirme avoir lu, compris et accepté les Conditions générales d'ADVFN et j'affirme etre un investisseur privé.
